OPK

OPKO Health, Inc. - 10-Q Summary (Period Ended June 30, 2009)

Business Context and Reporting Period

This is a Quarterly Report on Form 10-Q for OPKO Health, Inc., a specialty healthcare company focused on ophthalmic pharmaceuticals, diagnostics, and instrumentation. The reporting period covers the three and six months ended June 30, 2009. The company is an accelerated filer incorporated in Delaware.

Key Financial Metrics

Liquidity and Debt: The company holds approximately $40.9 million in cash, cash equivalents, and marketable securities. It has a fully utilized $12.0 million line of credit with a related party (The Frost Group, LLC) bearing 11% interest, due January 11, 2011.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 167% for the three months and 26% for the six months compared to the prior year periods. This was driven by increased international sales of the OCT/SLO product following the resolution of an FDA warning letter and the commencement of U.S. marketing.
• Gross Margin Improvement: The company moved from a gross deficit in the prior year periods to a positive gross margin of $0.58 million (Q2) and $1.32 million (YTD). This improvement resulted from cost reduction initiatives and supplier changes implemented in 2008.
• Reduced Operating Expenses:
  • R&D: Decreased significantly ($2.5M vs $5.5M in Q2; $8.2M vs $9.8M YTD) primarily due to the termination of the Phase III clinical trial for bevasiranib in March 2009.
  • SG&A: Decreased ($2.9M vs $3.2M in Q2; $6.2M vs $8.6M YTD) due to lower personnel costs and reduced equity-based compensation.
• Capital Raising: The company raised approximately $51 million in equity during the six months ended June 30, 2009, including a $31 million private placement and a $20 million investment from the Frost Gamma Investments Trust.

Outlook, Risks, and Management Commentary

• Product Development: The Phase III trial for bevasiranib was terminated. The company is now focusing on the Aquashunt clinical trial (for glaucoma) and the commercialization of its OCT/SLO instrumentation.
• Strategic Investments: OPKO invested $2.3 million in Sorrento Therapeutics, Inc. for an exclusive license to an antibody library for ophthalmology. The company also intends to invest $2.5 million in Cocrystal Discovery, Inc. in September 2009.
• Liquidity Outlook: Management believes current cash resources are sufficient to fund operations and debt service for the next 12 months. However, the company expects to incur substantial losses in the foreseeable future and will require additional funding for future clinical trials and commercialization.
• Risks: Key risks include the history of operating losses, the unproven nature of technologies, dependence on third-party manufacturers, and the need for substantial additional funding. The company has no experience manufacturing pharmaceutical products and relies on third parties.
• Legal Proceedings: A lawsuit filed by Ophthalmic Imaging Systems (OIS) was settled in May 2009 without admission of liability; the impact was not material.

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $40.9 million cash position against the projected burn rate for the Aquashunt trial and ongoing operations.
• Bevasiranib Termination: Confirm the final costs associated with the shutdown of the bevasiranib trial and the strategic pivot to other candidates.
• Related Party Transactions: Review the terms of the $12 million line of credit and the $51 million equity raise involving the Frost Group and related entities.
• Revenue Concentration: Assess the risk associated with international customers representing a significant portion of revenue (e.g., top four customers represented ~63% of Q2 revenue).
• Regulatory Status: Monitor the progress of the Aquashunt 510(k) application and the impact of the previous FDA warning letter on future manufacturing.